Novonesis A/S Class B NSIS_B

Investment increases production capacity, supports booming consumer demand and reinforces Wisconsin's leadership in dairy biosolutions West Allis Ribbon Cutting Anders Lund, Chief Operating Officer and Executive Vice President at Novonesis cuts the ribbon at the West Allis ceremony. West Allis Ribbon Cutting Group photo at the Novonesis West Allis ribbon cutting on Friday, September 25 WEST ALLIS, Wis., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Novonesis, a global leader in biosolutions, announced the

Expansion in Patalganga puts Novozymes under the spotlight Novozymes (CPSE:NSIS B) has come into focus after Novonesis announced a €600 million plan to expand its Patalganga site, with the aim of increasing biosolutions capacity for customers across high growth markets. For context, Novozymes shares last closed at DKK429.4. A 90-day share price return of 13.00% points to building momentum, even though the 1-year total shareholder return of 8.50% and the 5-year total shareholder return, which...

Today, Novonesis will initiate the first tranche (the “First Tranche”) of the EUR 1 billion multi-year share buyback program announced in Company Announcement No. 14, on August 19, 2026. Under the First Tranche, Novonesis will acquire B shares for an aggregate amount of up to EUR 75 million, with the First Tranche expected to end no later than December 17, 2026. Based on the closing share price on September 11, 2026, the First Tranche corresponds to around 1.3 million B shares. The shares acquir

Novonesis will invest €600 million to expand its site in Patalganga and build a state-of-the-art facility. This marks another step in the company's long-term growth strategy and continued investment in its global production footprint to meet increasing demand. COPENHAGEN, Denmark – September 2, 2026. Novonesis will expand its facility in Patalganga and build one of the world’s most advanced enzyme production facilities. The €600 million investment will increase Novonesis’ production capacity to

Novonesis (Novozymes) B (NVZMY) recently announced a total dividend of $0.37 per share, with the ex-dividend date set for 2026-08-31. This includes a $0.37 per share cash dividend payable on 2026-09-16. As investors look forward to this upcoming payment, the spotlight also shines on the company's dividend history, yield, and growth rates.

New Nebraska biotechnology program and scholarship build on education and workforce partnerships across Novonesis’ U.S. communities Production Operator Thein Win, Production Operator at Novonesis’ Blair biomanufacturing facility Student Tour Local high school students tour Novonesis biomanufacturing facility in Blair, Nebraska as part of Manufacturing Day Blair, Nebraska, Aug. 26, 2026 (GLOBE NEWSWIRE) -- As the U.S. biotechnology sector grows, developing the skilled workforce needed to turn sci

FUL vs. NVZMY: Which Stock Is the Better Value Option?

COPENHAGEN, Denmark – August 19, 2026. Novonesis delivered strong first half of 2026 at 8% organic sales growth. 2026 outlook: Organic sales growth increased to 7-8% (previously 5-7%), and the adjusted EBITDA margin expected at the higher end of the 37-38% range. Inaugural share buy-back program announced. Ester Baiget, President & CEO: “We continue to deliver strong results with positive momentum across all sales areas and in both developed and emerging markets, also driving strong profitabilit

Strong first half year at 8% organic sales growth. 2026 outlook: Organic sales growth increased to 7-8% and the adjusted EBITDA margin expected at the higher end of the 37-38% range. Inaugural share buy-back program announced. Ester Baiget, President & CEO: “We continue to deliver strong results with positive momentum across all sales areas and in both developed and emerging markets, also driving strong profitability and cash flow. Our sustained performance quarter after quarter underlines the g

The Board of Directors of Novonesis has approved an inaugural multi-year share buyback program in a total amount of EUR 1 billion to be initiated during the second half of 2026 and expected to be completed by the end of 2029. The program will be initiated and executed in accordance with authorizations granted by the Annual General Meeting. The vast majority of shares acquired under the program will be cancelled, while a smaller portion will be retained to meet obligations arising from employee s

COPENHAGEN, Denmark, August 12, 2026 – Novonesis today announced the launch of Optiva® Triticum, a new biosolution that helps pasta manufacturers increase flexibility in wheat sourcing while maintaining the texture, firmness and eating experience consumers expect. As fluctuations in durum wheat availability and pricing continue to challenge the pasta industry, producers are seeking new ways to reduce raw material costs and strengthen supply resilience. Optiva® Triticum enables greater use of sof

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Microbial Biostimulants Market size & share revenue was valued at approximately USD 5.10 Billion in 2024 and is expected to reach USD 5.64 Billion in 2025 and is expected to reach around USD 13.88 Billion by 2034, at a CAGR of 10.5% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are BASF SE, Syngenta AG, B

Novonesis to acquire remaining share of MicroBioGen to strengthen yeast capabilities COPENHAGEN, Denmark, August 10 – Novonesis has signed an agreement with the intent to acquire MicroBioGen, an Australian biotechnology company with leading scientific expertise in yeast strains for industrial applications, particularly in bioethanol. The acquisition builds on Novonesis’ 2013 investment in MicroBioGen and its current 23% stake, further strengthening a decade-long collaboration in advanced yeast s

Novozymes (CPSE:NSIS B) has drawn investor attention after recent share price moves, with the stock down about 5% year to date and about 13% over the past year on a total return basis. See our latest analysis for Novozymes. The share price has eased in recent months, with a 90 day share price return of a 1.77% decline and a 1 year total shareholder return down 12.74%, suggesting momentum has been fading despite a 3 year total shareholder return of 11.42%. If this kind of mixed performance has...

The annual Corbion General Shareholders Meeting held on 13 May 2026 approved the appointments of Per Falholt and Bob Elfring as members of the Supervisory Board. Per Falholt brings over 40 years of experience in research and development, innovation, and leadership in the biotechnology and life sciences sectors. He currently serves as Operating Partner at Forbion and is co-founder and Chief Scientific Officer at 21st.BIO. He also holds several board positions and previously led global R&D at Novo

FUL vs. NVZMY: Which Stock Is the Better Value Option?